Lakefront Biotherapeutics NV (LKFT)
Develops cancer and immune disease treatments, including cell therapies made directly for patients.
$28.06-0.00%Healthcare
StockGlow Score
Bearish
BearishBullish
1 year ago-14.2%
The outlook
LKFT is trading near the lower end of its 52-week range and sits below both its 50- and 200-day moving averages. Analyst targets average about 10% above the current price, suggesting modest upside from here. The stock carries a low trailing P/E of 3.3, though overall sentiment metrics remain subdued.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target -10% vs current price
Analyst price target
~12-month · 3 analysts$25.22average target-10.1% vs now
Now $28.06
Low $18.62High $29.89
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.84B
52-wk high
$37.78
52-wk low
$26.42
50-day avg
$28.68
200-day avg
$31.00
Trailing P/E
3.3